

Investigation of Neuroinflammatory Biomarkers and OnabotulinumtoxinA For Trigeminal Neuralgia Pain

Jacob Worm¹, Stine Maarbjerg¹, Niklas Rye Jørgensen^{2,3}, Lars Bendtsen^{1,3}, Henrik Winther Schytz^{1,3}

¹Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, ²Department of Clinical Biochemistry, Translational Research Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ³Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, Copenhagen, Denmark


Background



Objective

To investigate the efficacy of botulinum toxin and the role of neuroinflammation in trigeminal neuralgia


Injection Sites



Modified from Ferneini et al. *J Oral Maxillofac Surg.* 2021

Methods

A 16-week Double Blind Randomized Placebo Controlled Clinical Trial



Primary Endpoint

30% reduction of mean average daily pain at week 5

Relevance to Patient Care

- 1 A better understanding neuroinflammation's role in trigeminal neuralgia mechanisms
- 2 More trigeminal neuralgia patients could be treated with botulinum toxin injections

Contact



*Calcitonin gene-related peptide, Interleukin-1 β , Interleukin-2, Interleukin-6, C-reactive protein, Tumor Necrosis Factor α